Expedited diagnosis of pediatric tuberculosis using Truenat MTB-Rif Dx and GeneXpert MTB/RIF

Singh, Urvashi; Singh, Manjula; Sharma, Sangeeta; Mahajan, Neha; Bala, Kiran; Srivastav, Abhinav; Singh, Kh. Jitenkumar; Rao, M V V; Lodha, Rakesh; Kabra, Sushil Kumar

doi:10.1038/s41598-023-32810-2

Cited by 15 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Truenat MTB-RIF-Dx does not detect the rpoB Q432K and S441L mutations [110]. However, these mutations are rare, with less than 0.7% frequencies globally [110][111][112].…”

Section: Chip-based Real-time Micro Pcr Assaysmentioning

confidence: 93%

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Naidoo,

Perumal,

Ngema

et al. 2023

Pathogens

View full text Add to dashboard Cite

Global tuberculosis (TB) eradication is undermined by increasing prevalence of emerging resistance to available drugs, fuelling ongoing demand for more complex diagnostic and treatment strategies. Early detection of TB drug resistance coupled with therapeutic decision making guided by rapid characterisation of pre-treatment and treatment emergent resistance remains the most effective strategy for averting Drug-Resistant TB (DR-TB) transmission, reducing DR-TB associated mortality, and improving patient outcomes. Solid- and liquid-based mycobacterial culture methods remain the gold standard for Mycobacterium tuberculosis (MTB) detection and drug susceptibility testing (DST). Unfortunately, delays to result return, and associated technical challenges from requirements for specialised resource and capacity, have limited DST use and availability in many high TB burden resource-limited countries. There is increasing availability of a variety of rapid nucleic acid-based diagnostic assays with adequate sensitivity and specificity to detect gene mutations associated with resistance to one or more drugs. While a few of these assays produce comprehensive calls for resistance to several first- and second-line drugs, there is still no endorsed genotypic drug susceptibility test assay for bedaquiline, pretomanid, and delamanid. The global implementation of regimens comprising these novel drugs in the absence of rapid phenotypic drug resistance profiling has generated a new set of diagnostic challenges and heralded a return to culture-based phenotypic DST. In this review, we describe the available tools for rapid diagnosis of drug-resistant tuberculosis and discuss the associated opportunities and challenges.

show abstract

“…Truenat MTB-RIF-Dx does not detect the rpoB Q432K and S441L mutations [110]. However, these mutations are rare, with less than 0.7% frequencies globally [110][111][112].…”

Section: Chip-based Real-time Micro Pcr Assaysmentioning

confidence: 93%

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Naidoo,

Perumal,

Ngema

et al. 2023

Pathogens

View full text Add to dashboard Cite

show abstract

“…This Made in India product approved by the World Health Organization (WHO) is a classical demonstration of the practical applications of DH. [28][29][30] Mobile applications are also used to help rural healthcare providers identify and refer possible TB patients to the nearest microscopy center. 31 The author is the Principal Investigator of a pilot study in two remote districts in the state of Gujarat for technologically enabled TB screening using handheld X-ray machines and TrueNat on-site diagnostics.…”

Section: Sanjeevani Appmentioning

confidence: 99%

A Glimpse Into the Deployment of Digital Health in India

Krishnan, MCh (Neurosurgery), FACS, FICS, FAMS, PhD

2024

THMT

View full text Add to dashboard Cite

It is universally acknowledged that the wellbeing of any country, its prosperity and economic prowess depends on the health of its citizens. As the most populated country in the planet and an emerging economy, a solution for India, could well be a solution for the world. In the last eight years, the country has taken more than baby steps, to not just promote but to incorporate Digital Health in the core of the health care delivery system. Specific advantages, applications, regulatory and legal concerns and economic growth of DH are discussed.

show abstract

“…The tests are run using a near-POC dual-instrument system for the detection of MTB and reflex-based detection of rifampicin resistance. A recent study in India demonstrated that when using pediatric specimens including gastric aspirate, induced sputum, and bronchoalveolar lavage, sensitivity and specificity were comparable to the results obtained using Xpert assays [ 87 ].…”

Section: Evaluating Children With Presumptive Tbmentioning

confidence: 99%

Pediatric Tuberculosis: A Review of Evidence-Based Best Practices for Clinicians and Health Care Providers

Moore,

Graham,

Nandakumar

et al. 2024

Pathogens

View full text Add to dashboard Cite

Advances in pediatric TB care are promising, the result of decades of advocacy, operational and clinical trials research, and political will by national and local TB programs in high-burden countries. However, implementation challenges remain in linking policy to practice and scaling up innovations for prevention, diagnosis, and treatment of TB in children, especially in resource-limited settings. There is both need and opportunity to strengthen clinician confidence in making a TB diagnosis and managing the various manifestations of TB in children, which can facilitate the translation of evidence to action and expand access to new tools and strategies to address TB in this population. This review aims to summarize existing guidance and best practices for clinicians and health care providers in low-resource, TB-endemic settings and identify resources with more detailed and actionable information for decision-making along the clinical cascade to prevent, find, and cure TB in children.

show abstract

Expedited diagnosis of pediatric tuberculosis using Truenat MTB-Rif Dx and GeneXpert MTB/RIF

Cited by 15 publications

References 19 publications

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges

A Glimpse Into the Deployment of Digital Health in India

Pediatric Tuberculosis: A Review of Evidence-Based Best Practices for Clinicians and Health Care Providers

Contact Info

Product

Resources

About